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Purpose. Report a case of limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis. Design.
Interventional case report. Methods. A 32-year-old African American female with atopic keratoconjunctivitis (AKC) presented
with chronic dry eye and diﬀuse punctate epithelial erosions refractory to conservative treatment. She was initially managed with
cyclosporine ophthalmic 0.05% in addition to preservative-free artiﬁcial tears and olopatadine hydrochloride 0.2% for 6 months.
Shewaslaterplacedonautologousserumeyedrops(ASEDs)and4weeksintotreatmentdevelopedunilaterallimbitis.Thelimbitis
resolved shortly after stopping ASEDs in that eye; however, the drops were continued in the contralateral eye, which subsequently
developed limbitis within 2 weeks. ASEDs were discontinued in both eyes, and the patient has remained quiet ever since. Results.
Patient with a history of AKC and no prior history of limbitis developed limbitis shortly after starting ASEDs, which resolved
promptly after discontinuation of therapy with no subsequent recurrence of inﬂammation. Conclusion. ASEDs are widely used in
the treatment of complicated or treatment refractory dry eye. The potential side eﬀects should be kept in mind when prescribing
ASEDs for any patient, especially in those with underlying immunological diseases and circulating inﬂammatory factors.
1.Introduction
Ocular surface homeostasis is maintained by adequate tear
production, a stable tear ﬁlm, and healthy eyelid and ocular
surfaceanatomy[1].Aberrationsinanyofthesecomponents
can lead to dry eye and secondary complications of epithelial
erosions, ulceration, scarring, melting, or perforation [2].
Tears play an important role in ocular surface stability by
lubricatingtheeyeandpreventing cornealdesiccationaswell
as by providing nutritional, epitheliotropic, antimicrobial,
and antiapoptotic factors to the cornea and conjunctiva [3].
Thetreatmentofdryeyeisbasedupontheincitingcause,
the disease severity, and the presence of secondary com-
plications. Most cases of mild-to-moderate dry eye can be
managed with conventional therapy including preservative-
free artiﬁcial tear substitution, anti-inﬂammatory medica-
tions such as cyclosporine ophthalmic, punctal occlusion, or
lid revision [1] .H o w e v e r ,i nc a s e so fs e v e r ed r ye y eo ri n
the presence of secondary complications such as persistent
epithelial defects or visual impairment, more intensive ther-
apy is necessitated [2]. Autologous serum eye drops (ASEDs)
have been recommended for use in these cases given their
ability to both lubricate the eye and enhance the growth
and migration of the corneal epithelium via the presence of
nutritional, epitheliotropic, antiapoptotic, and antimicrobial
factors similar to natural tears [3].
However, there are reported complications associated
with the use of ASEDs [4]. In this paper, we describe the
case of a patient with atopic keratoconjunctivitis (AKC) who
was treated with ASEDs for dry eye associated with epithelial
erosions and subsequently developed bilateral limbitis.
2.CaseReport
A 32-year-old African-American female with a history of
atopic keratoconjunctivitis (AKC) was referred to our clinic
for chronic dry eye and diﬀuse punctate epithelial erosions
refractory to conservative treatment including preservative-
free artiﬁcial tears (Systane; Alcon, Fort Worth, Texas,
USA), olopatadine hydrochloride 0.2% (Patanol; Alcon, Fort
Worth, Texas, USA), and other topical mast cell stabilizers.
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foreign body sensation that was worse upon waking and
relieved only temporarily by artiﬁcial tears. She noted
blurring of her vision over the previous two months but
denied any symptoms of pain or red eye during the previous
year. Review of systems was notable for a history of eczema.
Her past ocular history was signiﬁcant for AKC and bilateral
open angle glaucoma. Her glaucoma was managed with
bilateral tube shunts and was stable. Past medical history was
unremarkable. She was taking loratadine daily for allergies
but no other medications. Family and social history were
noncontributory.
On examination, the patient’s corrected visual acuity
was 20/200 OD and 20/100 OS. IOP was 12mmHg OD
and 14mmHg OS with tube shunts in place. External
examination revealed bilateral moderate-to-severe dry eye
with diﬀuse punctate epithelial erosions. Conjunctiva was
clear OU. Decreased corneal sensation was present OU.
Bilateral 1-2 plus cortical cataract with a clear optical zone
was noted. Schirmer’s testing (with anesthetic) revealed
4mm of wetting OD and 5mm OS.
A clinical diagnosis of AKC with dry eye refractory to
conservativemedicalmanagementwasmade,andthepatient
was started on cyclosporine ophthalmic 0.05% (Restasis;
Allergan, Irvine, California) four times daily in addition to
preservative-free artiﬁcial tears (Systane) and olopatadine
hydrochloride 0.2% (Patanol) twice daily. The patient was
followed closely over the next 6 months and failed to
progress clinically. Follow-up exams had all shown diﬀuse
epitheliopathy with clear conjunctiva bilaterally. At that
point, ASEDs every two hours were added to the patient’s
regimen. The ASEDs were prepared by obtaining peripheral
blood (40mL) from the antecubital fossa and centrifuging at
1500to3000for20minutes.A20percentserumdilutionwas
prepared in a balanced saline solution and stored for use in a
sterile bottle at −20◦C. Each bottle was removed for use and
kept at 4◦C between applications.
Within a few weeks of starting treatment, the patient
returned to clinic with a 1-week history of a red right eye.
Her vision remained stable. Examination revealed moderate
limbal injection and elevation in the right eye. Left eye
was quiet. Corneal exam was unchanged. A diagnosis of
limbitis OD was made. It was suspected that the patient
could be having a reaction to the ASEDs given the prompt
development of limbitis after starting the drops with no
similar episodes observed during the previous several years
of observation. ASEDs were discontinued OD with the initi-
ation of prednisolone acetate ophthalmic 1.0% (Pred Forte;
Allergan, Irvine, California) four times daily for inﬂamma-
tion management. Other topicals were continued OU, and
A S E D sw e r ec o n t i n u e dO S .
At the two-week followup, patient reported prompt reso-
lutionofthelimbitisintherighteyewithin2daysofstopping
ASEDs, however, had developed interval limbitis OS with a
presentation similar to the contralateral eye (Figure 1). At
that time, the ASEDs were considered the most likely cause
of the patient’s reaction and were completely discontinued.




Figure 1: External photographs of the patient reported in our case.
Marked temporal limbal injection and focal conjunctival elevation
is apparent.
After 15 months of followup, the patient has shown no
signs or symptoms of limbitis in either eye. Patient continues
to experience symptomatic dry eye and diﬀuse corneal
epitheliopathy despite aggressive therapy. She is currently
being considered for a scleral contact lens.
3. Discussion
The use of ASEDs has been accepted as an alternative to
artiﬁcial tears for the management of severe dry eye and its
complications. The tear ﬁlm, as described above, maintains
ocular surface homeostasis through its nutritional as well
as epitheliotropic, antimicrobial, and antiapoptotic abilities
[3]. ASEDs, like natural tears, contain bioactive factors
including vitamin A, epithelial growth factor (EGF), trans-
forming growth factor-β (TGF-β), ﬁbronectin, albumin, α-
2 macroglobulin, the platelet-derived growth factor (PDGF-
AB), hepatocyte growth factor, and neuropeptides [5, 6].
These factors promote the growth and migration of corneal
epithelium allowing for more rapid healing of defects.
It has been shown that ASEDs are superior to artiﬁ-
cial tears in the management of dry eye and have been
demonstrated to eﬀectivelymanageSjogren-type dry eye[7],
persistent epithelial defects, neurotrophic keratopathy [8],
chronic graft-versus-host disease [9], superior limbic kerato-
conjunctivitis[10],andinLASIK-induceddryeye[11].Yet,a
number of complications are associated with ASEDs therapy.
As they are derived from blood, consideration of anemia,Case Reports in Ophthalmological Medicine 3
systemic disease, and blood-borne infection is required
[4]. ASEDs dropper-bottle microbial contamination has
also been reported, requiring strict sterile technique and
storage [12]. One group has described immunoglobulin
deposition in the cornea after ASEDs therapy for persistent
epithelial defect in recurrent herpes simplex keratitis [13]. In
addition,ASEDshavebeenrarelyassociatedwithdiscomfort,
epitheliopathy, bacterial conjunctivitis, and eye lid eczema
[4]. Previous studies have used concentrations of ASEDs
ranging from 20% to 100%, with no clear consensus on dose
or concentration eﬀect established [14].
In our patient with AKC, limbitis occurred after just few
weeks of 20% ASEDs therapy in a patient that had been
quietforthepreviousseveralyearsofobservation,makingan
adverse reaction the most likely cause of her inﬂammation.
AKC is a chronic ocular surface allergic inﬂammatory
condition that is sometimes refractory to conventional top-
ical therapy [15]. Immunologic ﬁndings in atopy include
increased levels of immunoglobulin E (IgE), eosinophils,
spontaneous histamine release from mast cells, and Th2 cells
secreting interleukin-4 (IL-4) and IL-5, and decreased Th1
cells secreting interferon γ [16]. While the exact cause of
our patient’s reaction remains unclear, it is possible that
immunologically active ingredients in the serum of atopic
patients could trigger ocular surface inﬂammation. These
mediators may gain access to the ocular surface in higher
concentrations with ASEDs, or these drops may allow those
mediators to bypass the partially impaired barrier between
the blood and ocular surface microenvironments.
This case provides evidence that ASEDs should be used
with close followup, especially in patients with AKC or
other immunological disorders. For example, we observed
another patient with ocular cicatricial pemphigoid and
keratinization whose ocular surface inﬂammation acutely
worsened following treatment with ASEDs. In addition, it
is possible that proinﬂammatory factors in the serum could
exacerbate ocular surface conditions after topical therapy.
In these situations, the use of ASEDs with topical anti-
inﬂammatory therapy and/or close followup may be advised.
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